Skip to main content
. 2013 Jan 27;4(1):153–162. doi: 10.18632/oncotarget.832

Table 4. Molecular analyses of the 40 treated patients treated on Phase I trials.

Molecular mutation or aberration Number of patients tested Number of patients with a mutation or aberration
KRAS 11 2
NRAS 7 0
BRAF 10 0
CKIT 3 0
EGFR 10 0
PI3K 9 0
GNAQ 1 0
PTEN Loss 3 0
ER IHC 6 0
PR IHC 6 0
HER-2/neu FISH 8 1

Abbreviations: IHC immunohistochemistry; FISH fluorescence in situ hybridization